U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C19H18N4O2
Molecular Weight 334.3718
Optical Activity ( + )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIMOBENDAN, (+)-

SMILES

COC1=CC=C(C=C1)C2=NC3=C(N2)C=CC(=C3)C4=NNC(=O)CC4C

InChI

InChIKey=GLBJJMFZWDBELO-UHFFFAOYSA-N
InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)

HIDE SMILES / InChI

Molecular Formula C19H18N4O2
Molecular Weight 334.3718
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/1660359

Pimobendan (INN, or pimobendane; tradenames Vetmedin, Acardi, and Heartmedin) is a veterinary medication. Under the trade name Acardi, it is available for human use in Japan. Usually, this medicine is used to treat acute heart failure and chronic heart failure (mild to moderate in severity). By increasing the calcium ion sensitivity to protein regulating myocardial contraction and also by inhibiting phosphodiesterase (PDE-III) activity, this medicine dilates the blood vessels and improves the symptoms of heart failure such as shortness of breath and difficulty in breathing. Pimobendan is metabolized into an active metabolite (desmethylpimobendan) by the liver. The parent compound, pimobendan, is a potent calcium sensitizer while desmethylpimobendan is a more potent phosphodiesterase III inhibitor. Pimobendan is 90–95% bound to plasma proteins in circulation. This may have implications in patients suffering from low blood protein levels (hypoproteinemia/hypoalbuminemia) and in patients that are on concurrent therapies that are also highly protein bound.

Originator

Curator's Comment: # Boehringer Ingelheim Pharma KG

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: sensitization of the contractile proteins to Ca2+
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
1996 Dec
The novel insulinotropic mechanism of pimobendan: direct enhancement of the exocytotic process of insulin secretory granules by increased Ca2+ sensitivity in beta-cells.
1998 Mar
Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension.
2003 Jul
Plasma concentration profile of orally administered pimobendan and plasma brain natriuretic peptide level in patients with severe heart failure.
2003 May
Treatment of congestive heart failure.
2003 Nov
Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
2003 Oct 4
Do medical house officers value the health of veterans differently from the health of non-veterans?
2004 Apr 7
Successful allogeneic bone marrow transplantation for acute myelogenous leukemia after drug-induced cardiomyopathy.
2004 Sep
Use of pimobendan in the management of heart failure.
2004 Sep
Increased mitral valve regurgitation and myocardial hypertrophy in two dogs with long-term pimobendan therapy.
2005
[If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
2005 Apr 15
Ca2+-sensitisers--a promising option to treat heart failure?
2005 Dec
Selective blockade of nicotinic acetylcholine receptors by pimobendan, a drug for the treatment of heart failure: reduction of catecholamine secretion and synthesis in adrenal medullary cells.
2005 Feb
[Cytokine antagonists and endothelin antagonists for therapy of heart failure].
2005 Feb 10
Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers.
2005 Jan
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
2005 Mar
Effect of pimobendan on cardiopulmonary baroreflex control of sympathetic nerve activity in healthy young men.
2005 Oct 30
A review of levosimendan in the treatment of heart failure.
2006
Positive inotropic effect of purified green tea catechin derivative in guinea pig hearts: the measurements of cellular Ca2+ and nitric oxide release.
2006 Dec 15
Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.
2006 Jul-Aug
Pimobendan in heart failure therapy--a silver bullet?
2006 Mar-Apr
[Subarachnoid hemorrhage complicated with different manifestations of transient abnormal left ventricular wall motion: two case reports].
2006 May
Preclinical dilated cardiomyopathy in the dobermann.
2006 May 27
Acute heart failure: inotropic agents and their clinical uses.
2006 Nov
New insights in the treatment strategy for pulmonary arterial hypertension.
2006 Oct
Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions.
2007
Effects of pimobendan for mitral valve regurgitation in dogs.
2007 Apr
A pilot study to assess the feasibility of a submaximal exercise test to measure individual response to cardiac medication in dogs with acquired heart failure.
2007 Aug
Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation.
2007 Jul 20
[Calcium sensitizer agents in heart failure therapy].
2007 May 28
[Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].
2007 May 28
[Calcium sensitizer: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
2007 May 28
Treatment options in myocarditis: what we know from experimental data and how it translates to clinical trials.
2007 Sep
Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
2008 Jul-Aug
Anaesthesia for the geriatric dog and cat.
2008 Jun 1
Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease".
2008 Mar-Apr
Alterations in vasomotor control of coronary resistance vessels in remodelled myocardium of swine with a recent myocardial infarction.
2008 May
Canine heart disease: progress and promise.
2008 Nov
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
2008 Sep-Oct
Cardiac sarcoidosis culminating in severe biventricular failure.
2009
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
2009 Dec
Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease.
2009 Mar-Apr
Transient tricuspid valve regurgitation following surgical treatment of cor triatriatum dexter in a dog.
2009 May
Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
2009 Nov-Dec
A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.
2009 Oct
Readability estimates for commonly used health-related quality of life surveys.
2009 Sep
Acute effect of pimobendan and furosemide on the circulating renin-angiotensin-aldosterone system in healthy dogs.
2009 Sep-Oct
Assessment of the pharmacological effects of inotropic drugs on left ventricular pressure and contractility: an evaluation of the QA interval as an indirect indicator of cardiac inotropism.
2009 Sep-Oct
Patients' self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death.
2010 Feb
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
2013 Dec
Patents

Sample Use Guides

Acute heart failure: usually for adults, one capsule (2.5 mg of pimobendan) once daily Chronic heart failure (mild to moderate in severity): usually for adults, one capsule (2.5 mg of pimobendan) twice daily after meals
Route of Administration: Oral
In Vitro Use Guide
composite platelet aggregation (area under the curve [AUC]) and maximal platelet aggregation (aggregation units [AUs]) at 10.0μM pimobendan were significantly decreased for collagen-induced aggregation (AUC, 349.7 ± 58.4 vs 285.1 ± 72.2; maximal platelet aggregation, 196.2 ± 25.8 AUs vs 161.5 ± 38.0 AUs), and the AUC and velocity of aggregation at 10.0μM pimobendan were significantly decreased for ADP-induced aggregation (AUC, 268.5 ± 35.1 vs 213.4 ± 77.2; velocity of aggregation, 15.7 ± 2.9 AUs/min vs 11.8 ± 3.5 AUs/min).
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:20:45 UTC 2023
Edited
by admin
on Sat Dec 16 11:20:45 UTC 2023
Record UNII
613JXV89SU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIMOBENDAN, (+)-
Common Name English
(+)-PIMOBENDAN
Common Name English
3(2H)-PYRIDAZINONE, 4,5-DIHYDRO-6-(2-(4-METHOXYPHENYL)-1H-BENZIMIDAZOL-5-YL)-5-METHYL-, (+)-
Systematic Name English
Code System Code Type Description
FDA UNII
613JXV89SU
Created by admin on Sat Dec 16 11:20:45 UTC 2023 , Edited by admin on Sat Dec 16 11:20:45 UTC 2023
PRIMARY
CAS
118428-38-9
Created by admin on Sat Dec 16 11:20:45 UTC 2023 , Edited by admin on Sat Dec 16 11:20:45 UTC 2023
PRIMARY
PUBCHEM
4823
Created by admin on Sat Dec 16 11:20:45 UTC 2023 , Edited by admin on Sat Dec 16 11:20:45 UTC 2023
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER